Company intelligence / Profile preview

Asubio Pharma

Kobe, Hyogo, Japan

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Asubio advanced several clinical programs including neuroprotectant agents for stroke and spinal cord injury to Phase 2. Its lead assets focused on neuroprotection with multimodal mechanisms, but were discontinued or merged into Daiichi Sankyo

Therapeutic areas: ImmunologyOtherCardiovascularNeurologyPulmonologyOncology
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Asubio Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asubio Pharma.

Explore the full profile